Skip to content
Home » Bristol Myers to Acquire RayzeBio in Deal Valued at $4.1 Billion

Bristol Myers to Acquire RayzeBio in Deal Valued at $4.1 Billion

    FEATURE Bristol Myers Squibb will acquire radiopharmaceutical therapeutics company RayzeBio for $62.50 a share in cash. RayZeBio close at $30.57 on Friday. In a press release, the companies said the total equity value of the deal is about $4.

    Read full NASCAR article on Yahoo Sports

    Read all NASCAR articles